“We are pleased to finalize this important MOU with New Brunswick”, said Abony in a release. “Not only is it the result of productive and open negotiations, but it is an endorsement of the way Nuuvera operates and what we stand for. We will keep working with the Government of New Brunswick, and governments across Canada, to help create a safe, high-quality industry that meets the needs of all cannabis consumers.”

It’s been a busy week for Nuuvera in New Brunswick. Earlier this week, the company announced that it had purchased a building on the west side of Saint John and would establish a state-of-the-art laboratory in Saint John that will process, manufacture and distribute pharmaceutical-grade medical marijuana derivative products.

This will be Nuuvera’s second facility of this kind in Canada. The company also has a presence in Europe.

“With offices in Toronto, Tel Aviv, Hamburg, and Milan, we are positioned to serve diversified international markets with medical grade cannabis products, and our New Brunswick operations will form a critical piece of our research and development efforts that will keep us on the leading edge of product innovation,” said Abony.